Source: Pharmac
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018 and the 2019/20 Invitation to Tender, dated 1 November 2019.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:
- For new listings, by 4pm on 11 September 2020 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or the new listing date above (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Cyclizine lactate |
Inj 50 mg per ml, 1 ml; |
$14.95 |
$21.53 |
Hameln |
1 December 2020 |
1 May 2021 |
Nausicalm |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
DV Limit |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Cyclizine lactate |
Inj 50 mg per ml, 1 ml; |
$14.95 |
$21.53 |
Hameln |
1% |
1 December 2020 |
1 May 2021 |
Nausicalm |
2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently unlisted pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|
|
Pimecrolimus1 |
Crm 1%; |
$28.50 |
Elidel |
1 December 2020 |
1 March 2021 |
|
1 Special Authority criteria will apply as consulted on 11 August 2020. |
|||||
1 The following Special Authority criteria will apply:
Special Authority for Subsidy
Initial application only from a dermatologist, paediatrician or ophthalmologist, or any relevant practitioner on the recommendation of a dermatologist, paediatrician or ophthalmologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:
Both:
- Patient has atopic dermatitis on the eyelid; and
- Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure.
The following restriction will apply:
Maximum of 15 g per prescription
The following note will apply:
Note: a maximum of 15 g per prescription and no more than one prescription per 12 weeks.
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Escitalopram |
Tab 10 mg; |
$1.11 |
$1.07 |
Escitalopram (Ethics) |
1 May 2021 |
1 October 2021 |
Escitalopram – Apotex |
|
Escitalopram |
Tab 20 mg; |
$1.90 |
$1.92 |
Escitalopram (Ethics) |
1 May 2021 |
1 October 2021 |
Escitalopram – Apotex |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to currently unlisted pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|
|
Pimecrolimus2 |
Crm 1%; 15 g |
$28.50 |
Elidel |
1 December 2020 |
1 March 2021 |
|
2 Hospital restriction criteria will apply as consulted on 11 August 2020. |
|||||
2 The following hospital restrictions will apply:
Restricted
Initiation
Dermatologist, paediatrician or ophthalmologist
Both:
- Patient has atopic dermatitis on the eyelid; and
- Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure.
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Escitalopram |
Tab 10 mg |
$1.11 |
$1.07 |
Escitalopram (Ethics) |
1% |
1 May 2021 |
1 October 2021 |
Escitalopram – Apotex |
|
Escitalopram |
Tab 20 mg |
$1.90 |
$1.92 |
Escitalopram (Ethics) |
1% |
1 May 2021 |
1 October 2021 |
Escitalopram – Apotex |
Tender declines – Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2018/19 Invitation to Tender, dated 1 November 2018, and
- the 2019/20 Invitation to Tender, dated 1 November 2019.
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Loperamide hydrochloride [split market] |
Tab 2 mg |
2019/20 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Brimonidine Tartrate with Timolol Maleate |
Eye drops 0.2% with timolol maleate 0.5% |
|
Colistin Sulphomethate |
Inj 150 mg |
|
Disulfiram |
Tab 200 mg |
|
Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride |
Soln 4% with adrenaline 0.1 % and tetracaine hydrochloride 0.5%, 5 ml syringe |
|
Neostigmine metisulfate |
Inj 2.5 mg per ml, 1 ml |
|
Noradrenaline |
Inj 0.06 mg per ml, 50 ml syringe |
|
Noradrenaline |
Inj 0.1 mg per ml, 100 ml bag |
|
Noradrenaline |
Inj 0.12 mg per ml, 100 ml bag |
|
Noradrenaline |
Inj 0.16 mg per ml, 50 ml syringe |
|
Octreotide (somatostatin analogue) |
Inj 50 mcg per ml, 1 ml |
|
Octreotide (somatostatin analogue) |
Inj 100 mcg per ml, 1 ml |
|
Octreotide (somatostatin analogue) |
Inj 500 mcg per ml, 1 ml |
|
Silver Sulphadiazine |
Crm 1% (pack size of 100 g or less) |
|
Thiotepa |
Inj 15 mg |
|
Thiotepa |
Inj 100 mg |
|
Tramadol hydrochloride |
Oral soln 10 mg per ml |
|
Travoprost |
Eye drops 0.004% |
For products included in the 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.
Last updated: 31 August 2020
